Cyclopharm Limited (ASX: CYC) - ETF Exposure
Current share price for CYC : $0.510 0.04 (7.27%)+
Cyclomedica Limited (CYC) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a health technology company that is a leader in functional lung ventilation imaging. The Company's proprietary product Technegas is a clinical market leader in diagnostic imaging and is available in 66 countries.
CYC General Information +
| ASX Code | CYC |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 64 |
| CYC Share Price | $0.510 |
| Day High | $0.545 |
| Day Low | $0.510 |
| Last Close | $0.550 |
| CYC Share Price Movement | $0.04 ( 7.27% ) |
Prices as at 16:40, 1 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Already own an Australian ETF? You may already have meaningful exposure to CYC
Cyclopharm Limited (CYC) is held across 1 ETF spanning strategies that include health care equipment exposure . Its weighting in those funds means performance can have an outsized influence - when CYC moves, funds like DACE that hold it can move with it.
For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to CYC , while the average exposure across all 1 ETF that hold it is around 0% .
Top ETF holdings
Last updated: ETF data and holdings as at 1 September 2026
Own CYC directly or through an ETF?
How does holding Cyclopharm Limited (CYC) shares directly compare to ETFs that include it?
|
CYC Direct
|
DACE
ASX |
|
|---|---|---|
| Holdings | 1 company | 485 holdings |
| CYC Weight | 100% | 0% |
| Diversification | Single Stock | Broad |
| Annual Cost | Brokerage only | 0.28% p.a. |
| Approx. Yield | - | 2.94% |
| Star Ratings | - |  |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CYC's direct yield. Annual cost uses each ETF's MER.
CYC Exposure on $10,000 investment
How a $10,000 investment in Cyclopharm Limited (CYC) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Cyclopharm Limited (CYC) | Direct share | $0.510 | 0% | $0 | $10,000 |
| Dimensional Australian Core Equity (Managed Fund) (DACE) | Equity - Australia Strategy | $19.400 | -1.02% | -$102 | $9,898 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
Cyclopharm Limited (CYC) ETFs
1 ETF hold Cyclopharm Limited (CYC).
| ETF | CYC Weight | MER | Yield |
|---|---|---|---|
| Dimensional Australian Core Equity (Managed Fund) (DACE) | 0% | 0.28% | 2.94% |
Cyclopharm Limited (CYC) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 0.5¢ | 0% | 1 Sep 2023 | 11 Sep 2023 | - | - | - |
| HFResult | 0.5¢ | 0% | 27 Mar 2023 | 4 Apr 2023 | - | - | - |
| Result | 0.5¢ | 0% | 2 Sep 2022 | 12 Sep 2022 | - | - | - |
See all dividends from Cyclopharm Limited (CYC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Cyclopharm Limited (CYC) price-sensitive announcements
CYC - CYC 1H2026 Results Summary
Cyclopharm Limited reported its fifth consecutive record half with a 14% increase in reven
Cyclopharm Limited (CYC)
24 Aug 2026 | 8:09 AM
24 Aug 2026 | 8:09 AM
CYC - Half Yearly Report and Accounts
Cyclopharm Limited's half-yearly report for the period ending June 30, 2026, highlights a
Cyclopharm Limited (CYC)
24 Aug 2026 | 8:09 AM
24 Aug 2026 | 8:09 AM
CYC - New US Lung Imaging Guidelines Name Technegas as Preferred A
Cyclopharm Limited announced that new US lung imaging guidelines have named their product,
Cyclopharm Limited (CYC)
29 Jul 2026 | 8:31 AM
29 Jul 2026 | 8:31 AM
CYC - Immediate 11-Site Technegas Rollout at University Hospitals
Cyclopharm Limited has announced a significant agreement with University Hospitals in Clev
Cyclopharm Limited (CYC)
15 Jul 2026 | 8:29 AM
15 Jul 2026 | 8:29 AM
Cyclopharm Limited (CYC) Recent ASX Announcements
CYC Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$13.88 | -$12.60 | -1.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$13.21 | -$12.80 | 28.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$9.28 | -$10.00 | 39.60% | 0.00 | 0.50 | 0.30% | 0.0% |
CYC Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Cochlear Limited (COH) | $8,758M | -0.3136 | 0.2540 | 0.0785 | 32.6038 | 25.9998 | 24.1076 | 2.58% | 2.68% | 2.91% |
| Cyclopharm Limited (CYC) | $69M | -0.0179 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $21,371M | 0.1388 | 0.1647 | 0.1748 | 54.9372 | 47.1696 | 40.1525 | 1.19% | 1.29% | 1.46% |
| ResMed Inc. (RMD) | $19,538M | 9.5922 | 0.0984 | 0.0886 | 21.4532 | 19.5306 | 17.9409 | 1.08% | 1.18% | 1.27% |
CYC Directors
| Name | Position | Start Date |
|---|---|---|
| Mr James S McBrayer | Chief Executive Officer, Managing Director, Company Secretary | 3 Jun 2008 |
| Mr Douglas Ernest Charles Cubbin | Non-Executive Chairman, Non-Executive Director | 4 May 2026 |
| Ms Dianne Margaret Angus | Non-Executive Director | 10 Aug 2021 |
| Dr Gregory George King | Non-Executive Director | 27 Sep 2022 |
Cyclopharm Limited (CYC) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Mar 2026 | HEANEY, David | Buy | Direct Shares | 21,052 | $0.950 | $19,999.400 |
| 12 Mar 2026 | BARROW, Kevin | Buy | Indirect Shares | 5,263 | $0.950 | $4,999.850 |
| 12 Mar 2026 | WIGGLESWORTH, John | Buy | Direct Shares | 21,052 | $0.950 | $19,999.400 |
See all changes in directors' interest & trades for Cyclopharm Limited (CYC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CYC Management
| Name | Position |
|---|---|
| Jason Smith | Chief Financial Officer |
| Mathew Farag | Chief Operating Officer |
CYC Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cyclopharm Limited (CYC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 13,211,332 (12.20%) | Anglo Australian Christtan and Charitable Fund |
| 12,002,783 (11.31%) | Regal Funds Management Pty Ltd |
| 11,444,962 (10.57%) | Barings Acceptance Limited |
| 9,867,556 (8.88%) | National Nominees Ltd |
| 9,188,008 (8.49%) | Chemical Overseas Limited |
| 6,644,758 (6.14%) | CVC Limited |
| 7,067,962 (5.86%) | Investors Mutual Limited |
CYC Calendar of Events
| Date | Event |
|---|---|
| 23 August 2027 | Report (Interim) |
| 26 March 2027 | Report (Annual) |
| 24 February 2027 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
